INT244600

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.18
First Reported 2008
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 5
Total Number 6
Disease Relevance 3.12
Pain Relevance 1.64

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (POSTN) cell adhesion (POSTN) proteinaceous extracellular matrix (POSTN)
extracellular matrix organization (POSTN)
POSTN (Homo sapiens)
Pain Link Frequency Relevance Heat
peripheral neuropathy 26 100.00 Very High Very High Very High
Opioid 2 99.56 Very High Very High Very High
tricyclic antidepressant 2 99.20 Very High Very High Very High
dexamethasone 116 98.06 Very High Very High Very High
anticonvulsant 2 97.28 Very High Very High Very High
Gabapentin 2 96.32 Very High Very High Very High
Serotonin 2 95.84 Very High Very High Very High
Duloxetine 2 93.68 High High
Inflammation 6 92.48 High High
corticosteroid 17 68.96 Quite High
Disease Link Frequency Relevance Heat
Peripheral Neuropathy 26 100.00 Very High Very High Very High
Recurrence 14 100.00 Very High Very High Very High
Rheumatoid Arthritis 92 99.84 Very High Very High Very High
Shock 4 98.70 Very High Very High Very High
Neuropathic Pain 30 94.60 High High
Cancer 61 94.48 High High
INFLAMMATION 4 92.48 High High
Drug Induced Neurotoxicity 2 86.80 High High
Demyelinating Disease 4 65.16 Quite High
Sprains And Strains 13 62.80 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Periostin and PSA relapse free survival
Negative_regulation (survival) of Periostin associated with recurrence
1) Confidence 0.18 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2903527 Disease Relevance 0.48 Pain Relevance 0
One class encodes proteins known to contribute to osteogenic differentiation and/or inhibit hMSC growth (FHL2, POSTN, LOX, LOXL1, SPARC, TMSB4X, CTHR1, FST, TGFB1) while a second contains markers for a closely related differentiation fate of hMSC, chondrogenesis (CHI3LI, COL1A1, COL3A1, COL6A3, COL8A1, COL12A1, CTGF, LUM).
Negative_regulation (inhibit) of POSTN
2) Confidence 0.10 Published 2008 Journal BMC Syst Biol Section Body Doc Link PMC2527292 Disease Relevance 0.12 Pain Relevance 0.03
A variety of agents are used for symptomatic relief of boretzomib associated PN including opioids, tricyclic antidepressants such as nortryptline, anticonvulsants such as gabapentin, serotonin-norepeinephrine reuptake inhibitors such as duloxetine, nonsteroidal anti-inflammatory agents, vitamins, and nutritional supplements such as ?
Negative_regulation (relief) of PN associated with inflammation, anticonvulsant, peripheral neuropathy, duloxetine, serotonin, gabapentin, tricyclic antidepressant and opioid
3) Confidence 0.06 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2990320 Disease Relevance 0.87 Pain Relevance 0.62
For example, the incidence of grade 3 or higher neuropathy with VMP decreased from 14% to 2% with twice weekly vs weekly bortezomib with preliminary outcome data showing no loss in efficacy.46 Interestingly, patients treated with the combination of the heat shock protein (HSP)-90 inhibitor tanesipmycin and bortezomib have not developed Grade 3 PN, suggesting a possible neuroprotective effect of this novel agent.89 Of note, development/exacerbation of PN has also not been observed to date with the novel proteasome inhibitor carfilzomib, suggesting that this may not be a class specific effect.90,91
Neg (not) Negative_regulation (developed) of PN associated with shock, neuropathic pain and peripheral neuropathy
4) Confidence 0.06 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2990320 Disease Relevance 1.19 Pain Relevance 0.48
Dexamethasone treatment had a biphasic effect, increasing MK mRNA precociously, between PN1 and PN5, and then decreasing content at PN10 and PN15.
Negative_regulation (decreasing) of PN10 associated with dexamethasone
5) Confidence 0.00 Published 2009 Journal Respir Res Section Body Doc Link PMC2739515 Disease Relevance 0.23 Pain Relevance 0.26
Dexamethasone treatment had a biphasic effect, increasing MK mRNA precociously, between PN1 and PN5, and then decreasing content at PN10 and PN15.
Negative_regulation (decreasing) of PN15 associated with dexamethasone
6) Confidence 0.00 Published 2009 Journal Respir Res Section Body Doc Link PMC2739515 Disease Relevance 0.23 Pain Relevance 0.26

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox